AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior version, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently Amended): A medicament composition comprising as an active ingredient a compound or a physiologically acceptable salt thereof represented by the following general formula (I):



(I)

wherein R^1 represents a dicarba-*closo*-dodecaboran-yl group which may ~~have one or more substituents selected from the group consisting of~~ be substituted with a lower alkyl group ~~, a lower alkenyl group, carboxyl group, a lower alkoxycarbonyl group, amino group, hydroxyl group, a lower hydroxyalkyl group, a mono- or di-lower alkylcarbamoyl-substituted alkyl group, a lower alkanoyl group, an aryl group which may be substituted, and a lower aralkyl group which may be substituted~~; R^2 represents carboxyl group [[,]] or a lower alkoxy carbonyl group ~~, or hydroxyl group~~ ; X represents ~~a single bond or~~ a linking group selected from the group consisting of the groups represented by the following formulas:



wherein, Y^1, Y^2, Y^3, Y^4, Y^5, Y^6, and Y^7 independently represent oxygen atom or -N(R^3)- wherein R^3 represents hydrogen atom or a lower alkyl group; Y^8 represents oxygen atom, -N(R^4)- wherein R^4 represents hydrogen atom or a lower alkyl group, -CO-, -CH_2-, or -C(=CH_2)-; R^5, R^6, and R^7 independently represents hydrogen atom or one or more substituents on the phenyl group; R^8 represents a lower alkyl group or an aryl group which may be substituted, R^9 represents a lower alkyl group, and R^{10} represents an aryl group which may be substituted.

Claims 2-4 (Canceled)

Claim 5 (Currently Amended): A compound or a salt thereof represented by the following general formula (I) :



(I)

wherein R^1 represents a dicarba-*closo*-dodecaboran-yl group which may ~~have one or more substituents selected from the group consisting of~~ be substituted with a lower alkyl group ~~, a lower alkenyl group, carboxyl group, a lower alkoxycarbonyl group, amino group, hydroxyl group, a lower hydroxyalkyl group, a mono or di-lower alkylcarbamoyl-substituted alkyl group, a lower alkanoyl group, an aryl group which may be substituted, and a lower aralkyl group which may be substituted~~; R^2 represents carboxyl group [[,]] or a lower alkoxy carbonyl group ~~, or hydroxyl group~~; X represents ~~a single bond or~~ a linking group selected from the group consisting of the groups represented by the following formulas [[;]] :



wherein, Y^1, Y^2, Y^3, Y^4, Y^5, Y^6, and Y^7 independently represents oxygen atom or -N(R^3)- wherein R^3 represents hydrogen atom or a lower alkyl group; Y^8 represents oxygen atom, -N(R^4)- wherein R^4 represents hydrogen atom or a lower alkyl group, -CO-, -CH_2-, or -C(=CH_2)-; R^5, R^6, and R^7 independently represents hydrogen atom or one or more substituents on the phenyl group, R^8 represents a lower alkyl group or an aryl group which may be substituted; R^9 represents a lower alkyl group; and R^{10} represents an aryl group which may be substituted~~,~~

~~provided that when X is a single bond,~~

~~the compound wherein R^1 is unsubstituted dicarba-*closo*-dodecaboran-yl group and R^2 is hydroxyl group, and~~

~~the compound wherein R^1 is dicarba-*closo*-dodecaboran-yl group substituted with p-hydroxyphenyl group and R^2 is hydroxyl group are excluded~~.

Claims 6 and 7 (Canceled)

Claim 8 (New): A method of binding a receptor and a ligand, comprising binding a nuclear receptor and a nuclear receptor ligand in the presence of a compound or a physiologically acceptable salt thereof represented by the general formula (I) as recited in claim 5.